ACCREDITATION

GOAL STATEMENT

This CME conference series aims to deliver a comprehensive educational update that highlights the most clinically relevant advances in chronic liver and gastrointestinal (GI) diseases. The 1.5-day conferences focus on topics such as viral hepatitis (B & C), fatty liver disease, primary biliary cholangitis, complications of cirrhosis including hepatic encephalopathy and thrombocytopenia, hepatocellular carcinoma, opioid-induced constipation, and inflammatory bowel disease including management of complications such as iron-deficiency anemia.

TARGET AUDIENCE

Gastroenterologists, hepatologists, internists, family practitioners, surgeons, physician assistants, nurse practitioners, fellows/residents in training, registered nurses, and other healthcare professionals with an interest in GI and liver diseases.

 

STATEMENT OF NEED / PROGRAM OVERVIEW

Digestive diseases include a wide spectrum of disorders affecting the oropharynx and alimentary canal, liver and biliary system, and pancreas. Chronic GI disorders are common in the US, and the prevalence is increasing. Considerable overlap can be found in the symptoms of serious GI diseases and the symptoms of benign or functional GI diseases. Noninvasive diagnostic tests, sensible clinical evaluation plans, and a clear understanding of disease progression will enhance patient assessment/management and identify the right patients for referral to GI specialists. For patients with a confirmed diagnosis of a chronic GI disorder, advances in the understanding of the clinical impact of evolving treatment options offer new choices for managing these conditions.

 

The conference format will consist of lectures, Q&A/panel discussions, and parallel breakout sessions for in-depth discussions of high-interest topics.

 

CME LEARNING OBJECTIVES

Upon completion of this conference, participants should be better able to:

  • Describe evolving patient management and treatment strategies for chronic liver and GI disease

  • Integrate significant advances in therapeutic and diagnostic modalities into their clinical practices

  • Apply the latest clinical research, including future therapies and their role in the context of the current clinical paradigm

 

 

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Gastrointestinal and Liver Association of the Americas (GALA), and the Texas Liver Institute (TLI). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

 

The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

 

ANCC ACCREDITATION 

Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

 

A maximum of 10.3 contact hours may be earned for successful completion of this activity.

 

 

ABIM MAINTENANCE OF CERTIFICATION (MOC) POINTS

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to
11.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE OF CONFLICTS OF INTEREST

All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Staff at the Annenberg Center for Health Sciences at Eisenhower and Gastrointestinal and Liver Association of the Americas (GALA) have no relationships to disclose.

 

LEARNER ASSURANCE STATEMENT

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

  

AMERICANS WITH DISABILITIES ACT

The event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact us prior to the event at 877-925-9535 for assistance. Please note: Onsite requests will be addressed to the best of our ability.

This activity is supported by educational grants from AbbVie, Gilead,
Intercept Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Prometheus Laboratories Inc., and Salix Pharmaceuticals.

Jointly provided by the Annenberg Center for Health Sciences 
at Eisenhower, the Gastrointestinal and Liver Association of the Americas (GALA), and the Texas Liver Institute.

www.galamericas.org